Biognosys and Siemens Healthineers have entered a strategic agreement to expedite the diagnostic protein biomarkers discovery and assay development.
This deal will combine Biognosys’ expertise in unbiased biomarker discovery technologies and solutions with Siemens Healthineers’ biomarker assay development, lab testing and commercialisation capabilities.
Biognosys CEO and founder Oliver Rinner said: “With this agreement, we can enable our biopharmaceutical customers to use the power of our proprietary discovery proteomics solution for novel biomarker identification and bring these biomarkers into clinical applications with Siemens Healthineers’ diagnostic assay development expertise.”
